Publish time: 2023-03-17 00:00:00
12A-1080214
US and TW application pending
We invent a method of treating and preventing fibromyalgia. Our invention is to repurpose darapladib (a PAF-AH inhibitor) to treatment fibromyalgia by block PAF-AH that catalyzes production of the algogenic LPC16:0 during stress exposure. The invention is based on the results of animal study: LPC16:0 generated under upon oxidative stress mediates the stress-induced nociceptive activation and contribute to development of fibromyalgia-like pain in mice. By reducing LPC16:0 generation, darapladib can be used as analgesics and preventive treatment in fibromyalgia and other stress-related pain disorders. Compared with the existed treatment, the new therapy works on blocking the disease development rather than transient symptom relieving.
- In comparison with the current treatment, the new therapeutic method works on blocking the development of fibromyalgia rather than transient symptom relieving.
- A therapeutic method can be used for prevention of fibromyalgia development
- Less side effects on the central nervous system in comparison with pregabalin and other current analgesics (like sedation and dizziness).
- Clinical treatment.
- Therapeutic and preventive treatment for fibromyalgia
Chen, Chih-Cheng, Hung Chih-Hsien
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

METHODS OF TREATMENT AND PREVENTION OF FIBROMYALGIA AND STRESS-RELATED PAIN DISORDERS